The formation of scars at a wound site is reduced by contacting the wound site with an effective dose of an inhibitor of focal adhesion kinase (FAK) formulated in a pullulan hydrogel The release profile of the FAK inhibitor can be adjusted according to the nature of the wound, e.g., excisional wounds, burn wounds, etc.

A balloon catheter for treating, preventing, or reducing the recurrence of a stricture and/or cancer, or for treating benign prostatic hyperplasia (BPH), in a non-vascular body lumen; the ballon catheter comprising: An elongated balloon; a coating layer overlying an exterior surface of the balloon wherein the coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent; and a length-control mechanism (600) which stretches and elongates the balloon during deflation, giving the balloon a smaller cross-sectional deflated profile for tracking through the body lumen and for removal after treatment.

Disclosed is a drug eluting balloon for a balloon catheter. The drug eluting balloon comprises a balloon body (100) and a coating (200), and the coating (200) comprises a water-soluble adhesive layer (210), an isolating layer (220) and a drug layer (230) from the inside out. After the drug eluting balloon is pushed to a diseased part, the balloon body (100) is expanded, and the water-soluble adhesive layer (210) dissolves due to scouring by a blood flow, such that the isolating layer (220) and the drug layer (230) are separated from an outer surface of the balloon body (100) and adhere to a blood vessel wall. The provision of the isolating layer (220) can effectively suppress the water-soluble adhesive layer (210) from removing part of the drug layer (230) during dissolution, and after the drug layer (230) adheres to and makes contact with the blood vessel wall, the isolating layer can also reduce the scouring effect on the drug layer (230) by the blood flow, thereby reducing the loss of drugs, allowing the drugs to be taken in by the blood vessel wall to the greatest extent, greatly improving the utilization rate of the drugs and improving the treatment effect while also preventing toxic and side effects brought about by large doses of the drugs. Moreover, the isolating layer (220) can also realize the slow release of the drug layer (230), such that the drug layer (230) can provide treatment for a long time, and a good treatment effect can be obtained.

The field of materials and manufacturing methods involving single or multi-solvent, excipient and polymer-free drug coating formulations for production of microsphere coated drug delivery techniques.

Disclosed is a drug delivery system that specifically carries and releases an active substance to a target organ or tissue. The coating of the shape memory component constituting the drug delivery system enhances the biocompatibility and controlled delivery of the active substance previously loaded into the coating material to the target organ or tissue

Provided are a magnesium alloy stent with improved corrosion resistance, and a method for producing same. The bioabsorbable stent including a core structure of a magnesium alloy, the stent is composed of: a first anticorrosive layer containing magnesium fluoride as a main component formed on the core structure, and a second anticorrosive layer coated with a diamond-like carbon on the first anticorrosive layer.

The present disclosure generally relates to implantable devices including a releasable nitrite ion and to methods of preparing and using such compositions and devices. In one embodiment, the device is a stent, for example, a vascular stent. In another embodiment, the nitrite ion is ionically bound to an inorganic ion.

The present invention provides new classes of phenol compounds, including those derived from tyrosol and analogues, useful as monomers for preparation of biocompatible polymers, and biocompatible polymers prepared from these monomeric phenol compounds, including novel biodegradable and/or bioresorbable polymers. These biocompatible polymers or polymer compositions with enhanced bioresorbabilty and processability are useful in a variety of medical applications, such as in medical devices and controlled-release therapeutic formulations. The invention also provides methods for preparing these monomeric phenol compounds and biocompatible polymers.

The present invention relates to a method for coating catheter balloons with the pharmacological agent paclitaxel and the biological and biodegradable polymer composition shellac and optionally further components. Moreover the present invention relates to paclitaxel and shellac coated catheter balloons obtained according to the coating methods disclosed herein as well as the use of such coated catheter balloons for the short time release of the pharmaceutically active agent paclitaxel for prophylaxis and treatment of restenosis especially restenosis caused by angioplasty. The coated catheter balloons can be used alone or in combination with a coated or uncoated stent crimped on the catheter balloon before or after the coating with shellac and paclitaxel.

Drug-eluting devices and methods for the treatment of tumors of the pancreas, biliary system, gallbladder, liver, small bowel, or colon, are provided. Methods include deploying a drug-eluting device having a film which includes a mixture of a degradable polymer and a chemotherapeutic drug, wherein the film has a thickness from about 2 μm to about 1000 μm, into a tissue site and releasing a therapeutically effective amount of the chemotherapeutic drug from the film to treat the tumor, wherein the release of the therapeutically effective amount of the drug from the film is controlled by in vivo degradation of the polymer at the tissue site.